TY - JOUR T1 - Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe. JF - ERJ Open Res Y1 - 2021 A1 - Andreas Jung A1 - Annalisa Orenti A1 - Fiona Dunlevy A1 - Elina Aleksejeva A1 - Egil Bakkeheim A1 - Vladimir Bobrovnichy A1 - Siobhán B Carr A1 - Colombo, Carla A1 - Harriet Corvol A1 - Rebecca Cosgriff A1 - Géraldine Daneau A1 - Deniz Dogru A1 - Pavel Drevinek A1 - Vukic, Andrea Dugac A1 - Isabelle Fajac A1 - Alice Fox A1 - Stojka Fustik A1 - Gulmans, Vincent A1 - Harutyunyan, Satenik A1 - Hatziagorou, Elpis A1 - Irena Kasmi A1 - Hana Kayserová A1 - Elena Kondratyeva A1 - Uroš Krivec A1 - Halyna Makukh A1 - Malakauskas, Kestutis A1 - Edward F McKone A1 - Mei-Zahav, Meir A1 - de Monestrol, Isabelle A1 - Hanne Vebert Olesen A1 - Rita Padoan A1 - Tsitsino Parulava A1 - Maria Dolores Pastor-Vivero A1 - Luísa Pereira A1 - Guergana Petrova A1 - Andreas Pfleger A1 - Liviu Pop A1 - Jacqui G van Rens A1 - Milan Rodic A1 - Marc Schlesser A1 - Valérie Storms A1 - Oxana Turcu A1 - Lukasz Woz Niacki A1 - Panayiotis Yiallouros A1 - Zolin, Anna A1 - Damian G Downey A1 - Naehrlich, Lutz AB -

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with cystic fibrosis (pwCF) can lead to severe outcomes.

METHODS: In this observational study, the European Cystic Fibrosis Society Patient Registry collected data on pwCF and SARS-CoV-2 infection to estimate incidence, describe clinical presentation and investigate factors associated with severe outcomes using multivariable analysis.

RESULTS: Up to December 31, 2020, 26 countries reported information on 828 pwCF and SARS-CoV-2 infection. Incidence was 17.2 per 1000 pwCF (95% CI: 16.0-18.4). Median age was 24 years, 48.4% were male and 9.4% had lung transplants. SARS-CoV-2 incidence was higher in lung-transplanted (28.6; 95% CI: 22.7-35.5) non-lung-transplanted pwCF (16.6; 95% CI: 15.4-17.8) (p≤0.001).SARS-CoV-2 infection caused symptomatic illness in 75.7%. Factors associated with symptomatic SARS-CoV-2 infection were age >40 years, at least one F508del mutation and pancreatic insufficiency.Overall, 23.7% of pwCF were admitted to hospital, 2.5% of those to intensive care, and regretfully 11 (1.4%) died. Hospitalisation, oxygen therapy, intensive care, respiratory support and death were 2- to 6-fold more frequent in lung-transplanted non-lung-transplanted pwCF.Factors associated with hospitalisation and oxygen therapy were lung transplantation, cystic fibrosis-related diabetes (CFRD), moderate or severe lung disease and azithromycin use (often considered a surrogate marker for infection and poorer lung function).

CONCLUSION: SARS-CoV-2 infection yielded high morbidity and hospitalisation in pwCF. PwCF with forced expiratory volume in 1 s <70% predicted, CFRD and those with lung transplants are at particular risk of more severe outcomes.

VL - 7 CP - 4 M3 - 10.1183/23120541.00411-2021 ER -